Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.69 |
| ▸ | JAK3 | P52333 | 20/20 | 0.69 |
| ▸ | JAK2 | O60674 | 11/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | TYK2 | P29597 | 1/20 | 0.66 |
| ▸ | SYK | P43405 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341716 | 1.00 | JAK1 (0.69) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL524014 | 0.92 | JAK1 (0.69) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL525327 | 0.92 | JAK1 (0.73) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29752114 | 0.91 | JAK1 (0.69) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL341649 | 0.91 | JAK1 (0.73) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29609965 | 0.91 | JAK1 (0.72) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL339403 | 0.91 | JAK1 (0.72) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL524922 | 0.90 | JAK1 (0.72) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL341243 | 0.90 | JAK1 (0.79) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29610010 | 0.90 | JAK1 (0.79) | JAK1JAK3JAK2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |